Heterocyclic chalcone analogues as potential anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 422-432

  Sharma, Vikas ^a   Kumar, Vipin ^a   Kumar, Pradeep ^b,c  

^a KURUKSHETRA UNIVERSITY   (India)

^b CHITKARA UNIVERSITY   (India)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Anticancer agents; Chalcone analogues; Heterocyclic chalcone analogues

Indexed keywords

4 AMINOQUINOLINE; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; CISPLATIN; COUMARIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FERROCENE; IMIDAZOLE; INDOLE; IONONE DERIVATIVE; MITOXANTRONE; MORPHOLINE; PACLITAXEL; PIPERAZINE; PIPERIDINE; PROTEIN P53; PYRAZOLE; PYRIDINE; PYRIDINE DERIVATIVE; PYRROLOQUINOLINEQUINONE; QUERCETIN; THIOMORPHOLINE; THIOPHENE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; BREAST CANCER; BREAST CARCINOMA; CELL CYCLE; CELL PROLIFERATION; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; LEUKEMIA; MULTIDRUG RESISTANCE; NEOPLASM; PROSTATE CANCER; REVIEW; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHALCONES; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876707914     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313030006     Document Type: Review

References (115)

1. Star, A.E.; Marby, T.J. Flavanoid front exudates from two Jamaican ferns, Pityrogrammu tartarea and P. calomelanos. Phytochemistry, 1971, 10(11), 2817-2818.
2. Dhar, D.N. The Chemistry of Chalcones and Related Compounds, Wiley & sons: New York, 1981.
3. Sukumaran, K.; Kuttan, R. Screening of 11 ferns of cytotoxic and antitumour potential with special reference to Pityrngrumma calomelanos. J. Ethnopharmacol., 1991, 34(1), 93-96.
4. Akihisa, T.; Tokuda, H.; Ukiyaa, M.; Iizukaa M.; Schneidera, S.; Ogasawarac, K.; Mukainakab, T.; Iwatsukid, K.; Suzukie, T.; Nishino, H. Chalcones, coumarins, and flavanones from the exudates of Angelica keiskei and their chemopreventive effects. Cancer Lett., 2003, 201(2), 133-137.
5. Inamori, Y.; Baba, K.; Tsujibo, H.; Taniguchi, M.; Nakata, K.; Kozawa, M. Antibacterial activity of two chalcones, xanthoangelol and 4-hydroxyderricin, isolated from the root of Angelica keiskei KOIDZUMI. Chem. Pharm. Bull., 1991, 39(6), 1604-1605.
6. Rao, Y.K.; Fang, S.H.; Tzeng, Y.M. Synthesis and biological evaluation of 3′, 4′, 5′-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. Bioorg. Med. Chem., 2009, 17, 7909-7914.
7. Katsori, A.M.; Hadjipavlou-Litina, D. Chalcones in cancer: understanding their role in terms of QSAR. Curr. Med. Chem., 2009, 16(9), 1062-1081.
8. Tomas-Barberan, F.A.; Michael, N.C. Flavones, chalcones and dihydrochalcones - nature, occurrence and dietary burden. J. Sci. Food Agric., 2000, 80(7), 1073-1080.
9. World Health Organisation. Media centre: Cancer Fact Sheet No297. http://www.who.int/mediacentre/factsheets/fs297/en/index.html (Accessed November 20, 2010)http://www.who.int/mediacentre/factsheets/fs297/en/index.html(Accessed.
10. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011. CA Cancer J. Clin., 2011, 61(4), 212-236.
11. Carter, S.K.; Slavik, M. Chemotherapy of Cancer. Ann. Rev. Pharmacol. Toxicol., 1974, 14(1), 157-183.
12. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 2006, 71(10), 1397-1421.
13. Yadav, V.R.; Prasad, S.; Sung, B.; Aggarwal, B.B. The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int. Immunopharmacol., 2011, 11(3), 295-309.
14. Ahcene, B.; Xavier, R.; Boutonnat J. Chalcones derivatives acting as cell cycle blockers: potential anti-cancer drugs? Curr. Drug Targets, 2009, 10(4), 363-371.
15. Lawrence, N. J.; McGown, A.T. The chemistry and biology of antimitotic chalcones and related enone systems. Curr. Pharm. Des., 2005, 11, 1679-1693.
16. Batovska, D.I.; Todorova, I.T. Trends in utilization of the pharmacological potential of chalcones. Curr. Clin. Pharmacol., 2010, 5(1), 1-29.
17. Ducki, S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. Anticancer Agents Med. Chem., 2009, 9(3), 336-47.
18. Ni, L.; Meng, C.Q.; James, A.S. Recent advances in therapeutic chalcones. Expert Opin. Ther. Pat., 2004, 14(12), 1669-1691.
19. Nowakowska, Z. A review of anti-infective and anti-inflammatory chalcones. Eur. J. Med. Chem., 2007, 42(2), 125-137.
20. Kontogiorgis, C.; Mantzanidou, M.; Hadjipavlou-Litina, D. Chalcones and their potential role in inflammation. Mini-Rev. Med. Chem., 2008, 19(12), 1224-1242.
21. Harborne, J.B.; Williams, C.A. Advances in flavonoid research since 1992. Phytochemistry, 2000, 55(6), 481-504.
22. Oak, M.H.; El Bedoui, J.; Schini-Kerth, V.B. Antiangiogenic properties of natural polyphenols from red wine and green tea. J. Nutr. Biochem., 2005, 16, 1-8.
23. Dinkova-Kostova, A.T.; Abeygunawardana, C.; Talalay, P. Chemoprotective properties of phenylpropenoids chemoprotective properties of phenylpropenoids, bis(benzylidene)cycloalkanones, and related michael reaction acceptors: Correlation of potencies as phase 2 enzyme inducers and radical scavengers. J. Med. Chem., 1998, 41, 5287-5296.
24. Dimmock, J.R.; Elias, D.W.; Kandepu, N.M. Bioactivities of chalcones. Curr. Med. Chem., 1999, 6(12), 1125-1149.
25. Opletalova, V.; Sedivy, D. Chalcones and their heterocyclic analogues as potential antifungal chemotherapeutics. Ces. Slov. Farm., 1999, 48(6), 252-255.
26. Opletalova, V. Chalcones and their heterocyclic analogues as potential therapeutic agents for bacterial diseases. Ces. Slov. Farm., 2000, 49(6), 278-284.
27. Opletalova, V.; Jahodarl J.D.; Opletal L. Chalcones and their analogues as potential therapeutic agents of diseases of the cardiovascular systems. Ces. Slov. Farm., 2003, 52(1), 12-19.
28. Opletalova, V.; Ricicarova, P.; Sedivy, D.; Meltrova, D.; Krivakova, J. Chalcones and their heterocyclic analogues as potential medicaments. Folia Pharm. Univ. Carol., 2000, 25, 21-33.
29. Vanhoecke, B.; Derycke, L.; Marck, V.V.; Depypere H.; Keukeleire D.D.; Bracke M. Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int. J. Cancer, 2005, 117(6), 889-895.
30. Heidari, M.R.; Foroumadi, A.; Noroozi, H.; Samzadeh-Kermani, A.; Azimzadeh, B.S. Study of the anti-inflammatory and analgesic effects of novel rigid benzofuran-3,4-dihydroxy chalcone by formalin, hot-plate and carrageenan tests in mice. Pak. J. Pharm. Sci., 2009, 22(4), 395-401.
31. Heidari, M.R.; Foroumadi, A.; Amirabadi, A.; Samzadeh-Kermani, A.; Azimzadeh, B.S.; Eskandarizadeh, A. Evaluation of anti-inflammatory and analgesic activity of a novel rigid 3, 4-dihydroxy chalcone in mice. Ann. N. Y. Acad. Sci., 2009, 1171, 399-406.
32. Gafner, S.; Wolfender, J.; Mavi, S.; Hostettmann, K. Antifungal and antibacterial chalcones from Myrica serrata. Planta Med., 1996, 62(1), 67-69.
33. Sivakumar, P.M.; Sreenivasan, S.P.; Kumar, V.; Doble, M. Synthesis, antimycobacterial activity evaluation, and QSAR studies of chalcone derivatives. Bioorg. Med. Chem. Lett., 2007, 17(6), 1695-1700.
34. Li, R.; Kenyon, G.L.; Cohen, F.E.; Chen, X.; Gong, B.; Dominguez, J.N.; Davidson, E.; Kurzban, G.; Miller, R.E.; Nuzum, E.O.; Rosenthal, P.J. In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chem., 1995, 38(26), 5031-5037.
35. Domínguez, J.N.; Charris, J.E.; Lobo, G.; Moreno, M.M.; Riggione, F.; Sanchez, E.; Olson, J.; Rosenthal, P.J. Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur. J. Med. Chem., 2001, 36(6), 555-560.
36. Domínguez, J.N.; León, C.; Rodrigues J.; Gamboa de Domínguez, N.; Gut, J. Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J. Med. Chem., 2005, 48(10), 3654-3658.
37. Wu X.; Wilairat, P.; Go, M.L. Antimalarial activity of ferrocenyl chalcones. Bioorg. Med. Chem. Lett., 2002, 12(17), 2299-2302.
38. Domínguez, J.N.; León, C.; Rodrigues J.; Gamboa de Domínguez, N.; Gut, J.; Rosenthal, P.J. Synthesis and antimalarial activity of sulfonamide chalcone derivatives. IL Farmaco, 2005, 60(4), 307-311.
39. Liu, M.; Wilairat, P.; Croft, S.L.; Tand, A.L.-C.; Go, M.L. Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg. Med. Chem., 2003, 11(13), 2729-2738.
40. Hansa, R.H.; Guantai, E.M.; Lategan, C.; Smith, P.J.; Wan, B.; Franzblau, S.G.; Gut, J.; Rosenthal P.J.; Chibale, K. Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. Bioorg. Med. Chem. Lett., 2010, 20(3), 942-944.
41. Heidari, M.R.; Foroumadi, A.; Noroozi, H.; Samzadeh-kermani, A.; Azimzadeh, B.S. Study of the anti-inflammatory and analgesic effects of novel rigid benzofuran-3, 4-dihydroxy chalcone by formalin, hot-plate and carrageenan tests in mice. Pak. J. Pharm. Sci., 2009, 22(4), 395-401.
42. Nielsen, S.F.; Christensen, S.B.; Cruciani, G.; Kharazmi, A.; Liljefors, T. Antileishmanial Chalcones: Statistical Design, Synthesis, and Three-Dimensional Quantitative Structure-Activity Relationship Analysis. J. Med. Chem., 1998, 41(24), 4819-4832.
43. Zhai, L.; Chen, M.; Blom, J.; Theander, T.G.; Christensen, B.S.; Kharazmi, A. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J. Antimicrob. Chemother., 1999, 43(6), 793-803.
44. Wu, J.H.; Wang, X.H.; Yi, H.; Lee, K.H. Anti-AIDS agents 54. A potent anti-HIV chalcone and flavonoids from genus Desmos. Bioorg. Med. Chem. Lett., 2003, 13(10), 1813-1815.
45. Deng, J.; Sanchez, T.; Al-Mawsawi, L.Q.; Dayam, R.; Yunes, R.A.; Garofalo, A.; Bolger, M.B.; Neamati, N. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. Bioorg. Med. Chem., 2007, 15(14), 4985-5002.
46. Nakagawa-Goto K.; Lee, K.H. Anti-AIDS agents 68. The first total synthesis of a unique potent anti-HIV chalcone from genus Desmos. Tetrahedron Lett., 2006, 47(47), 8263-8266.
47. Kozmík, V.; Lhoták, P.; Odlerová, Z.; Palecek, J. Azabischalcones-a new class of potential antitubercular agents. J. Ceska Slov. Farm., 1998, 47(2), 87-90.
48. Sivakumar, P.M.; Kumar V.; Seenivasan, S.P.; Mohanapriya, J.; Doble, M. Experimental and theoretical approaches to enhance anti tubercular activity of chalcones. WSEAS Transact. Biol. Biomed., 2010, 7(2), 51-61.
49. Trivedi, J.C.; Bariwal, J.B.; Upadhyay, K.D.; Naliaparaa, Y.T.; Joshi, S.K.; Pannecouque, C.C.; Clercq, E.D.; Shah, A.K. Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Lett., 2007, 48(48), 8472-8474.
50. Sunairi, M.; Watanabe, K.; Suzuki, T.; Tanaka, N.; Kuwayama, H.; Nakajima, M. Effects of anti-ulcer agents on antibiotic activity against Helicobacter pylori. Eur. J. Gastroenterol. Hepatol., 1994, 6(Suppl 1), S121-124.
51. Kyogoku, K.; Hatayama, K.; Yokomori, S.; Saziki, R.; Nakane, S.; Sasajima, M.; Sawada, J.; Ohzeki, M.; Tanaka, I. Anti-ulcer effect of isoprenyl flavonoids. II. Synthesis and anti-ulcer activity of new chalcones related to sophoradin. Chem. Pharm. Bull., 1979, 27(12), 2943-53.
52. Sasajima, M.; Nakane, S.; Saziki, R.; Saotome, H.; Hatayama, K.; Kyogoku, K.; Tanaka, I. Studies on the anti-ulcer effects of isoprenyl flavonoids (1). The anti-ulcer effects of isoprenyl chalcone extracted from sophora subprostrata. Nippon Yakurigaku Zasshi, 1978, 74(8), 897-905.
53. Rossi G.V.; Avellino, J.D. An evaluation of the antihistaminic activity of a new series of chalcone derivatives. Am. J. Pharm. Sci. Support Public Health., 1957, 129(9), 324-331.
54. Yamamoto, T.; Yoshimura M.; Yamaguchi, F.; Kouchi, T.; Tsuji, R.; Saito, M.; Obata A.; Kikuchi, M. Anti-allergic activity of naringenin chalcone from a tomato skin extract. Biosci. Biotechnol. Biochem., 2004, 68(8), 1706-1711.
55. Wang, J.; Wang, N.; Yao, X.; Kitanaka, S. Structures and anti-histamine activity of chalcones & aurones compounds from Bidens parviflora Willd. Asian J. Tradition. Med., 2007, 2(1), 23-29.
56. Damazio, R.G.; Zanatta, A.P.; Cazarolli, L.H.; Chiaradia, L.D.; Mascarello, A.; Nunes, R.J.; Yunes, R.A.; Barreto Silva, F.R. Antihyperglycemic activity of naphthylchalcones. Eur. J. Med. Chem., 2010, 45(4), 1332-1337.
57. Damazio, R.G.; Zanatta, A.P.; Cazarolli, L.H.; Mascarello, A.; Chiaradia, L.D.; Nunes, R.J.; Yunes, R.A.; Barreto Silva, F.R. Nitrochalcones: Potential in vivo insulin secretagogues. Biochimie, 2009,91(11-12), 1493-1498.
58. Kaushik, S.; Kumar N.; Drabu, S. Synthesis and anti-convulsant activities of phenoxychalcones. Pharma Res., 2010, 3(1), 257-262.
59. Nielsen, S.F.; Boesen, T.; Larsen, M.; Schønning, K.; Kromann, H. Antibacterial chalcones-bioisosteric replacement of the 4′-hydroxy group. Bioorg. Med. Chem., 2004, 12(11), 3047-3054.
60. Bonesi, M.; Loizzo, M.R.; Statti, G.A.; Michel, S.; Tillequin, F.; Menichini, F. The synthesis and Angiotensin Converting Enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives. Bioorg. Med. Chem. Lett., 2010, 20(6), 1990-1993.
61. Ogawa, H.; Ohno, M.; Baba, K. Hypotensive and lipid regulatory actions of 4-hydroxyderricin, a chalcone from Angelica keiskei, in stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol., 2005, 32(1-2), 19-32.
62. Dong, X.; Du, L.; Pan, Z.; Liu, T.; Yang, B.; Hu, Y. Synthesis and biological evaluation of novel hybrid chalcone derivatives as vasorelaxant agents. Eur. J. Med. Chem., 2010, 45(9), 3986-3992.
63. Pruitt, R.; Sasi, N.; Freeman, M.L.; Sekhar, K.R. Radiosensitization of cancer cells by hydroxychalcones. Bioorg. Med. Chem. Lett., 2010, 20, 5997-6000.
64. Ivanova, Y.; Momekov, G.; Petrov, O.; Karaivanova, M.; Kalcheva, V. Cytotoxic mannich bases of 6-(3-aryl-2-propenoyl)-2(3H)-benzoxazolones. Eur. J. Med. Chem., 2007, 42(11-12), 1382-1387.
65. Hanm H.; Zhao, Y.; Cuthbertson, T.; Hartman, R.F.; Rose, S.D. Cell cycle arrest and apoptosis induction by an anticancer chalcone epoxide. Arch. Pharm., 2010, 343(8), 429-439.
66. Na, Y.; Nam, J.M. Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives. Bioorg. Med. Chem. Lett., 2011, 21(1), 211-214.
67. Kamal, A.; Ramakrishna, G.; Raju, P.; Viswanath, A.; Ramaiah, M.J.; Balakishan, G.; Pal-Bhadra, M. Synthesis and anti-cancer activity of chalcone linked imidazolones. Bioorg. Med. Chem. Lett., 2010, 20(16), 4865-4869.
68. Bhaskar, V.H.; Mohite, P.B. Synthesis, characterization and evaluation of anticancer activity of some tetrazole derivatives. J. Optoelectron. Adv. Mater., 2010, 2(4), 249-259.
69. Modzelewska, A.; Pettit, C.; Achanta, G.; Davidson, N.E.; Huang, P.; Khan, S.R. Anti-cancer activities of novel chalcone and bis-chalcone derivatives. Bioorg. Med. Chem. Lett., 2006, 14, 3491-3495.
70. Sashidhara, K.V.; Kumar, A.; Kumar, M.; Sarkar, J.; Sinha, S. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg. Med. Chem. Lett., 2010, 20(24), 7205-7211.
71. Valente, S.; Bana, E.; Viry, E.; Bagrel, D.; Kirsch, G. Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases. Bioorg. Med. Chem. Lett., 2010, 20, 5827-5830.
72. Ratković, Z.; Juranić, Z.D.; Stanojković, T.; Manojlović, D.; Vukićević, R.D.; Radulović, N.; Joksović, M.D. Synthesis, characterization, electrochemical studies and antitumor activity of some new chalcone analogues containing ferrocenyl pyrazole moiety. Bioorg. Chem., 2010, 38(1), 26-32.
73. Kamal, A.; Reddy, J.S.; Ramaiah, M.J.; Dastagiri, D.; Bharathi, E.V.; Sagar, M.V.P.; Pushpavalli, S.N.C.V.L.; Ray, P.; Pal-Bhadra, M. Design, synthesis and biological evaluation of imidazopyridine/ pyrimidine-chalcone derivatives as potential anticancer agents. Med. Chem. Commun., 2010, 1, 355-360.
74. Kumar, D.; Kumar, N.M.; Akamatsu, K.; Kusaka, E.; Harada, H.; Ito, T. Synthesis and biological evaluation of indolyl chalcones as antitumor agents. Bioorg. Med. Chem. Lett., 2010, 20(13), 3916-3919.
75. De Vincenzo, R.; Ferlini, C.; Distefano, M.; Gaggini, C.; Riva, A.; Bombardelli, E.; Morazzoni, P.; Valenti, P.; Belluti, F.; Ranelletti, F.O.; Mancuso, S.; Scambia, G. In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother. Pharmacol., 2000, 46(4), 305-312.
76. Boumendjel, A.; McLeer-Florin, A.; Champelovier, P.; Allegro, D.; Muhammad, D.; Souard, F.; Derouazi, M.; Peyrot, V.; Toussaint, B.; Boutonnat, J. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer, 2009, 9, 242.
77. Konieczny, M.T.; Konieczny, W.; Sabisz, M.; Skladanowski, A.; Wakieć, R.; Augustynowicz-Kopeć, E.; Zwolska, Z. Acid-catalyzed synthesis of oxathiolone fused chalcones. Comparison of their activity toward various microorganisms and human cancer cells line. Eur. J. Med. Chem., 2007, 42(5), 729-733.
78. Liu, X.; Go, M.L. Antiproliferative activity of chalcones with basic functionalities. Bioorg. Med. Chem. 2007, 15, 7021-7034.
79. Liu, X.; G. M.L. Antiproliferative properties of piperidinylchalcones. Bioorg. Med. Chem. 2006, 14, 153-163.
80. Insuasty, B.; Tigreros, A.; Orozco, F.; Quiroga, J.; Abonía, R.; Nogueras, M.; Sanchez, A.; Cobo, J. Synthesis of novel pyrazolic analogues of chalcones and their 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole derivatives as potential antitumor agents. Bioorg. Med. Chem., 2010, 18(14), 4965-4974.
81. De Vincenzo, R.; Ferlini, C.; Distefano, M.; Gaggini, C.; Riva, A.; Bombardelli, E.; Morazzoni, P.; Valenti, P.; Belluti, F.; Ranelletti, F.O.; Mancuso, S.; Scambia, G. In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother. Pharmacol., 2000, 46(4), 305-312.
82. Mishra, L.; Sinha, R.; Itokawa, H.; Bastow, K.F.; Tachibana, Y.; Nakanishi, Y.; Kilgorec, N.; Lee K.-H. Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polypyridyl complexes containing 2,6-(20-benzimidazolyl)-pyridine/chalcone as co-ligand. Bioorg. Med. Chem., 2001, 9, 1667-1671.
83. Kamal, A.; Shankaraiah, N.; Prabhakar, S.; Reddy, C.R.; Markandeya, N.; Reddy, K.L.; Devaiah, V.; Solid-phase synthesis of new pyrrolobenzodiazepine-chalcone conjugates: DNA-binding affinity and anticancer activity. Bioorg. Med. Chem. Lett., 2008, 18(7), 2434-2439.
84. Via, L.D.; Gia, O.; Chiarelotto, G.; Ferlin, M.G. DNA-targeting pyrroloquinoline-linked butenone and chalcones: Synthesis and biological evaluation. Eur. J. Med. Chem., 2009, 44(7), 2854-2861.
85. Kotra, V.; Ganapaty, S.; Adapa, S.R. Synthesis of a new series of quinolinyl chalcones as anticancer and anti-inflammatory agents. Ind. J. Chem., 2010, 49B, 1109-1116.
86. Ferrer, R.; Lobo, G.; Gamboa, N.; Rodrigues, J.; Abramju, C.; Jung, K.; Lei, M.; Charris J.E. Synthesis of [(7-Chloroquinolin-4-yl)amino]chalcones: Potential antimalarial and anticancer agents. Sci. Pharm., 2009, 77, 725-741.
87. Shi, H.B.; Zhang, S.J.; Ge, Q.F.; Guo, D.W.; Cai, C.M.; Hu, W.X. Synthesis and anticancer evaluation of thiazolyl-chalcones. Bioorg. Med. Chem. Lett., 2010, 20(22), 6555-6559.
88. Romagnoli R.; Baraldi, P.G.; Carrion, M.D.; Cara, C.L.; Cruz-Lopez, O.; Preti, D.; Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Zonta, N.; Balzarini, J.; Brancale, A.; Sarkar, T.; Hamel, E. Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Bioorg. Med. Chem., 2008, 16, 5367-5376.
89. Sharma, V.; Kumar, P.; Pathak, D. Biological importance of the indole nucleus in recent years: A comprehensive review. J. Het. Chem., 2010, 47, 491-502.
90. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Cruz-Lopez, O.; Cara, C.L.; Balzarini, J.; Hamel, E.; Canella, A.; Fabbri, E.; Gambari, R.; Basso, G.; Viola, G. Hybrid α-bromoacryloylamido chalcones. Design, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2009, 19(7), 2022-2028.
91. Robert, J.; Jarry, C. Multidrug resistance reversal agents J. Med. Chem., 2003, 46(23), 4805.
92. Ahmed-Belkacem, A.; Pozza, A.; Macalou, S.; Perez- Victoria, J. M.; Boumendjel, A.; Di Pietro, A. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anti-cancer Drugs, 2006, 17(3), 239-243.
93. Zamora, J. M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol., 1988, 33(4), 454.
94. Lee, J.S.; Paull, K.; Alvarez, M.; Hose, C.; Monks, A.; Grever, M.; Fojo, A.T.; Bates, S.E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 1994, 46(4), 627-638.
95. Liu, X.L.; Tee, H.W.; Go, M.L. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg. Med. Chem., 2008, 16, 171-180.
96. Petrusek, R. L.; Uhlenhopp, E. L.; Duteau, N.; Hurley, L.H. Reaction of anthramycin with DNA. Biological consequences of DNA damage in normal and xeroderma pigmentosum cell. J. Biol. Chem., 1982, 257, 6207.
97. Zhou, J.; Geng, G.; Batist, G.; Wu, J.H. Syntheses and potential anti-prostate cancer activities of ionone-based chalcones. Bioorg. Med. Chem. Lett., 2009, 19, 1183-1186.
98. Meng, C.Q.; Zheng, X.S.; Ni, L.; Ye, Z.; Simpson, J.E.; Worsencroft, K.J.; Hotema, M.R.; Weingarten, M.D.; Skudlarek, J.W.; Gilmore, J.M.; Hoong, L.K.; Hill, R.R.; Marino, E.M.; Suen, K.L.; Kunsch, C.; Wasserman, M.A.; Sikorski, J.A. Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-alpha-induced VCAM-1 expression. Bioorg. Med. Chem. Lett., 2004, 14(6), 1513-1517.
99. Seelig, A.; Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci., 2000, 12(1), 31-40.
100. Ducki, S.; Forrest, R.; Hadfield, J.A.; Kandall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett., 1998, 8(9), 1051-1056.
101. Bois, F.; Beney, C.; Boumendjel, A.; Mariotte, A.; Conseil, G.; Di Pietro, A. Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance. J. Med. Chem., 1998, 41(21), 4161.
102. Bois, F.; Boumendjel, A.; Mariotte, A.; Conseil, G.; Di Pietro, A. Synthesis and biological activity of 4-alkoxy chalcones: potential hydrophobic modulators of P-glycoprotein- mediated multidrug resistance. Bioorg. Med. Chem., 1999, 7(12), 2691.
103. Pati, H.N.; Holt, H.L.; LeBlanc, R.; Dickson, J.; Stewart, M.; Brown, T.; Lee, M. Synthesis and cytotoxic properties of nitro- and aminochalcones. Med. Chem. Res., 2005, 14, 19-25.
104. Xia, Y.; Yang, Z.Y.; Xia, P.; Bastow, K.F.; Nakanishi, Y.; Lee, K.H. Antitumor agents. Part 202: novel 2'-amino chalcones: design, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2000, 10(8), 699-701.
105. Dimmock, J.R.; Jha, A.; Zello, G.A.; Allen, T.M.; Santos, C.L.; Balzarini, J.; De Clercq, E.; Manavathu, E.K.; Stables, J.P. Pharmazie, 2003, 58, 227.
106. Shimiz, K.; Kondo, R.; Sakai, K.; Buabarn, S.; Dilokkunanant, U. A geranylated chalcone with 5α-reductase inhibitory properties from Artocarpus incisus. Phytochemistry, 2000, 54, 737-739.
107. Jayasinghe, L.; Rupasinghe, G.K.; Hara, N.; Fujimoto, Y. Geranylated phenolic constituents from the fruits of Artocarpus nobilis. Phytochemistry, 2006, 67(13), 1353-1358.
108. Nishimura, R.; Tabata, K.; Arakawa, M.; Ito, Y.; Kimura, Y.; Akihisa, T.; Nagai, H.; Sakuma, A.; Kohno, H.; Suzuki, T. Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol. Pharm. Bull., 2007, 30, 1878-1883.
109. Rodriguez, R.J.; Miranda, C.L.; Stevens, J.F.; Deinzer, M.L.; Buhler, D.R. Influence of prenylated and non-prenylated flavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. Food Chem. Toxicol., 2001, 39, 437-445.
110. Kong, K.W.Y.; Edler, M.C.; Hamel, E.; Mooberry, S.L.; Paige, M.A.; Brown, M.L. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg. Med. Chem., 2010, 18, 971-977.
111. Go, M.L.; Wu, X.; Liu, X.L. Chalcones: An update on cytotoxic and chemopreventive properties. Curr. Med. Chem., 2005, 12, 483-499.
112. Jing, H.; Zhou, X.; Dong, X.; Cao, J.; Zhu, H.; Lou, J.; Hu, Y.; He, Q.; Yang, B. Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Lett., 2010, 294(2), 167-177.
113. Lee, Y.M.; Lim do, Y.; Choi, H.J.; Jung, J.I.; Chung, W.Y.; Park, J.H. Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. J. Med. Food., 2009, 12, 8-14.
114. Fu, Y.; Hsieh T.C.; Guo, J.; Kunicki, J.; Lee, M.Y.; Darzynkiewicz, Z.; Wu, J.M. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra) causes G2 and late-G1arrests in androgen-independent PC3 prostate cancer cells. Biochem. Biophys. Res. Commun., 2004, 322, 263-270.
115. Desmulle, L.; Bellahcene, A.; Dhooge, W.; Comhaire, F.; Roelens, F.; Huvaere, K.; Heyerick, A.; Castronovo, V.; Dekeukeleire D. Antiproliferative properties of prenylated flavonoids from hops (Humulus lupulus L.) in prostate cancer cell lines. Phytomedicine, 2006, 13, 732-734.